# Eledon Pharmaceuticals Inc. (ELDN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1M  
**Price:** $3.57 (+3.18%)

> Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, a humanized anti-CD40L antibody that targets the CD40 ligand pathway, a well-validated biological mechanism for immune regulation. Tegoprubart is being evaluated across multiple therapeutic areas, including kidney allograft transplantation through the Phase 2 BESTOW trial, islet cell transplantation for type 1 diabetes management, and xenotransplantation procedures. The company is also exploring applications in amyotrophic lateral sclerosis treatment. Eledon's clinical development strategy encompasses Phase 2 studies demonstrating promising kidney function outcomes and favorable safety profiles compared to standard immunosuppressive regimens. The company is advancing toward Phase 3 clinical trials and regulatory discussions with the FDA. Eledon maintains active collaborations with leading transplant centers and research institutions to expand its therapeutic potential across multiple indication areas.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2016 | — | — | -$5M | -$6M | — |
| 2015 | — | — | -$45M | -$45M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2016 | $1M | $4M | -$3M | $1M | — |
| 2015 | $68M | $6M | $3M | $24M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$62M | — | — |
| 2024 | -$47M | — | — |
| 2023 | -$40M | — | — |
| 2022 | -$28M | — | — |
| 2021 | -$29M | — | — |
| 2020 | -$15M | — | — |
| 2019 | -$14M | — | — |
| 2018 | -$12M | — | — |
| 2017 | -$15M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/ELDN)